Skip to main content
. 2020 Oct 13;4(1):e1294. doi: 10.1002/cnr2.1294

FIGURE 3.

FIGURE 3

Kaplan‐Meier survival curve of the patients with neutrophil‐to‐lymphocyte ratio reduction. Among the 13 patients N/L ≥ 2.5 in group B, 6 (46.2%) patients had N/L reduction after combination therapy of sorafenib and TACE. The 3‐month, 6‐month, 1‐year and 2‐year survival for these 6 patients were 83.3%, 83.3%, 66.7% and 33.3%, respectively, compared to 57.1%, 28.6%, 14.3% and 0%, respectively, for the other 7 patients (P = .013)